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In the general population worldwide, colorectal cancer 
(CRC) is the third most commonly diagnosed cancer, with 
about 1 million cases and >500 000 deaths annually.1 In the 
United States, CRC is also the second leading cause of can-
cer death overall in men and women combined.2 The life-
time risk of CRC is about 5% to 6%.3 Most people with 
early colon cancer do not have any symptoms such that in 
many CRC patients their cancer is not detected until they 
present with metastasis and micrometastases.4,5 This results 
in an increasing global mortality from CRC, which is 
approximately 50% of incidence.1
Almost 40% to 50% of patients relapse and ultimately 
die of metastatic disease after undergoing curative surgery 
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Abstract
The acute apoptotic response to genotoxic carcinogens animal model has been extensively used to assess the ability of 
drugs and natural products like dietary components to promote apoptosis in the colon and protect against colorectal cancer 
(CRC). This work aimed to use this model to identify the main chemopreventative agent in extracts from an Australian 
mollusc Dicathais orbita, while simultaneously providing information on their potential in vivo toxicity. After 2 weeks of 
daily oral gavage with bioactive extracts and purified brominated indoles, mice were injected with the chemical carcinogen 
azoxymethane (AOM; 10 mg/kg) and then killed 6 hours later. Efficacy was evaluated using immunohistochemical and 
hematoxylin staining, and toxicity was assessed via hematology, blood biochemistry, and liver histopathology. Comparison 
of saline- and AOM-injected controls revealed that potential toxic side effects can be interpreted from blood biochemistry 
and hematology using this short-term model, although AOM negatively affected the ability to detect histopathological 
effects in the liver. Purified 6-bromoisatin was identified as the main cancer preventive agent in the Muricidae extract, 
significantly enhancing apoptosis and reducing cell proliferation in the colonic crypts at 0.05 mg/g. There was no evidence 
of liver toxicity associated with 6-bromoisatin, whereas 0.1 mg/g of the brominated indole tyrindoleninone led to elevated 
aspartate aminotransferase levels and a reduction in red blood cells. As tyrindoleninone is converted to 6-bromoisatin by 
oxidation, this information will assist in the optimization and quality control of a chemopreventative nutraceutical from 
Muricidae. In conclusion, preliminary data on in vivo safety can be simultaneously collected when testing the efficacy of new 
natural products, such as 6-bromoisatin from Muricidae molluscs for early stage prevention of colon cancer.
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alone.6 The risk of treatment failure is reduced by 35% 
among patients with stage III colon cancer treated with che-
motherapy, in comparison to surgery alone.7 The combina-
tion of fluorouracil, irinotecan, and leucovorin (FOLFIRI) 
is currently the standard and first-line chemotherapy for 
metastatic CRC.8 Nevertheless these therapies are far from 
curative and many serious side effects have been reported, 
such as peripheral sensory neuropathy,9 myelosuppression, 
mucositis,10-12 pulmonary embolus, myocardial infarction, 
and death.13 As a result of the morbidity associated with 
chemotherapy and poor prognosis of the disease, along with 
the large economic burden CRC presents,1 prevention of 
this disease is an important priority.
Lifestyle alteration is an important way to lower the risk 
of developing CRC, but implementing lifestyle changes is 
intrinsically difficult.14,15 However, the utilization of natural 
products as a source of novel chemopreventatives holds 
some promise for reducing CRC risk.16,17 It has been 
reported that the consumption of food with anticancer natu-
ral properties may result in a 10-fold decrease in the inci-
dence of CRC.18 However, in order to develop new natural 
products as medicinal foods or pharmaceutical agents, rig-
orous preclinical trials are required to meet both efficacy 
and safety standards. The acute apoptotic response to geno-
toxic carcinogens (AARGC) model has been developed for 
chemopreventative research; this model tests the ability of 
agents to reduce the incidence of CRC by inducing apopto-
sis of damaged colon cells.19 To date this model has been 
mainly used to test acute apoptotic response of dietary com-
ponents such as starches and oils20-22 and nonsteroidal anti-
inflammatory drugs.23 AARGC models are not typically 
used to collect toxicity data, presumably due to the known 
effects of azoxymethane (AOM) on the liver.24 However, in 
the short-term model for early stage prevention of CRC, 
rodents are killed just 6 hours after injection with AOM,21,22 
and therefore, it should be possible to simultaneously obtain 
some preliminary data on potential side effects of the 
extracts and compounds, if they can be detected over and 
above any effects of AOM. Maximizing the use of addi-
tional data from this model could provide an early indica-
tion of any products that may cause problematic side effects 
in longer-term animal models. Ultimately this could help 
reduce the total number of animals required for preclinical 
testing by allowing prioritization of compounds that are 
both effective and likely to be safe and thereby help satisfy 
the requirements of animal ethics committees.
The Muricidae are a family of predatory marine mol-
luscs (whelks) that provide a source of high-protein meat 
for people throughout Asia, Europe, and Central and South 
America. They also form the basis of some rare traditional 
medicines that have been used for thousands of years.25 
Muricids are well known for the production of brominated 
indole derivatives, including the ancient dye Tyrian pur-
ple.26 The brominated isatin and indole precursors of Tyrian 
purple from the Muricidae family and in particular the 
Australian species Dicathais orbita, are known for their 
anticancer activity (reviewed in Benkendorff et al25). In an 
in vitro study, Edwards et al27 revealed that tyrindoleninone 
inhibited cell growth (IC
50
 39 µM) and induced apoptosis in 
female reproductive cancers cell lines, with 10- to 100-fold 
specificity over freshly isolated human granulosa cells. 
Semipurified 6-bromoisatin and tyrindoleninone in our pre-
vious in vitro study induced apoptosis and inhibited the pro-
liferation of both HT29 and Caco2 cells.28 Furthermore, 
Muricid extract containing a mixture of tyrindoleninone 
and 6-bromoisatin was found to be effective for enhancing 
colonic apoptotic index in a dose-dependent manner in 
mice.29 However, further in vivo testing of the crude 
Muricidae extract has indicated the potential for idiosyn-
cratic gastrointestinal and liver toxicity.30 Thus, the aim of 
this new study was first to establish whether the short-term 
AARGC model can be used to assess any potential side 
effects caused by purified extracts using blood and liver 
analysis. Second, we aimed to determine the minimum dose 
of crude extract required to enhance the AARGC response 
(0.25 and 0.5 mg/g vs 0.125 and 1 mg/g doses previously 
tested29). Finally, we aimed to confirm which of the bromi-
nated indoles in crude muricid extracts are responsible for 
initiating apoptosis in AOM-damaged colon cells in vivo, 
along with any associated negative side effects, after sepa-
rating into fractions enriched in tyrindoleninone and 
6-bromoisatin.
Materials and Methods
Hypobranchial Gland Extraction, Flash Column 
Chromatography, and Chemical Analysis
A total of 1378 Dicathais orbita (1146 small ones from 2 to 
4 cm and 222 large ones from 4 to 7 cm) were collected 
from a sea-based abalone farm at Elliston, South Australia 
(Permit No. 9902638) and frozen at −20°C. Hypobranchial 
glands were dissected from all frozen Dicathais orbita and 
soaked in chloroform and methanol (1:1, v/v, high-perfor-
mance liquid chromatography grade; Sigma Aldrich) under 
agitation at room temperature. The extract was prepared 
according to the method previously described by Westley et 
al.29 All extracts were combined to obtain a total weight of 
7.83 g crude extract, which was then stored at −20°C until 
use. Flash silica chromatography pressurized with nitrogen 
gas was used to purify tyrindoleninone and 6-bromoisatin 
according to Esmaeelian et al.28 The extract was passed 
through a silica column and the fractions were collected; 
briefly, tyrindoleninone was purified as a bright orange 
fraction using dichloromethane and hexane (1:4, v/v) and 
6-bromoisatin was subsequently semipurified using 10% 
methanol in dichloromethane as the solvent system. Both 
fractions were dried and analyzed along with the crude 
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extract, by high-performance liquid chromatography 
(Waters Alliance) coupled to a mass spectrometer (MS; 
Micromass, Quatro micro) and stored at −20°C. Liquid 
chromatography (LC)/MS separation was performed on a 
Hydro-RP C18 column with parallel UV/Vis diode-array 
detection (300 and 600 nm), a flow rate of 1 mL/min using 
a gradient of acetonitrile in water with 0.1% formic acid, 
according to the methods established by Westley and 
Benkendorff.31
In Vivo Rodent Model
In this experiment, an established rodent model was used 
for early stage prevention of colon cancer.19,21,29,32 Male 
mice (wild-type C57BL/6J), 10 weeks old, were obtained 
from the Animal Resource Centre, Perth, Western Australia. 
Animal ethics and protocol were approved by the Animal 
Welfare Committee at Flinders University (Approval 
Number: 751/10). The mice were maintained at the tem-
perature of 22 ± 2°C and humidity of 80 ± 10% with a 
12-hour light/dark cycle. The mice were given water and 
food (rodent chow) ad libitum and monitored daily for any 
sign of illness, stool consistency, rectal bleeding, and nor-
mal behavior such as grooming. All mice were weighed at 
days 1, 5, 10, and 14 of the experiment.
The mice were divided randomly into 7 treatment and 2 
control groups (10 mice per group) and housed in 18 cages 
(5 mice per cage). Treatment groups included the following: 
(1) 0.5 mg/g crude extract, (2) 0.25 mg/g crude extract, (3) 
0.1 mg/g tyrindoleninone, (4) 0.05 mg/g tyrindoleninone, 
(5) 0.25 mg/g tyrindoleninone, (6) 0.1 mg/g semipurified 
6-bromoisatin, and (7) 0.05 mg/g semipurified 6-bromois-
atin. The extracts and purified compounds were adminis-
tered to mice by daily oral gavage in 100 µL sunflower oil 
(Golden Fields, New South Wales, Australia) supplemented 
with 0.02% vitamin E (Sigma Aldrich) for 2 weeks. There 
were also 2 control groups gavaged with sunflower oil (con-
taining 0.02% vitamin E) only. At the end of the 2-week 
period each mouse in all of the treatment groups and one of 
the control groups was injected with a single intraperitoneal 
(ip) injection of AOM (Sigma Aldrich, Australia) at a dos-
age of 10 mg/kg bodyweight, to induce DNA damage. A 
second control group received a saline injection instead of 
the AOM. The mice were euthanized 6 hours later by cervi-
cal dislocation under ketamine/xylazine anesthesia. The 
colon was excised immediately postmortem. Two centime-
ters of distal colon were fixed in 10% buffered formalin (24 
hours) and subsequently embedded in paraffin for histologi-
cal and immunohistological examination.
Histopathological Evaluation of the Liver
Histopathological variables are indicative of toxicity 
induced by cytotoxic or antimitotic drugs.33 The liver was 
therefore removed from each mouse and weighed. Liver 
weight was standardized by measuring the percentage of 
the liver weight divided by the body weight for each mouse. 
Livers were then fixed in 10% buffered formalin and 
embedded in paraffin. Four-micrometer sections of liver 
were stained with hematoxylin and eosin for histopatho-
logical examination of potential toxicity34 under light 
microscopy (Olympus, BH-2). Hepatotoxicity indictors that 
were assessed included porphyrin, hepatocellular hyperpla-
sia and hypertrophy, mallory bodies, hemosiderin, sinusoi-
dal dilation, congestion, hemorrhage, lipofuscin, steatosis 
(fatty change), necrosis, and inflammation.33,35
Blood Analysis (Hematology and Biochemistry)
Before euthanizing the mice, blood samples (0.5-1 mL) 
were obtained by cardiac puncture into heparinized vacu-
tainer tubes, under anesthesia and transferred to Gribbles 
Veterinary Pathology laboratory, Adelaide, South Australia, 
for hematology and biochemistry analysis. The samples 
were run through the Abbott Cell Dyn 3700 analyzer for 
hematology assessment and Siemens Advia 1800 chemistry 
analyzer for biochemistry analysis. The blood levels of liver 
enzymes including aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), and alkaline phosphatase 
(ALP) were assessed as indicators of hepatotoxicity.36
Measurement of Apoptosis Using Hematoxylin 
Staining
The apoptotic epithelial cells of distal colon sections were 
determined by hematoxylin staining as described by Hu et 
al.32 Distal colon sections were embedded in paraffin, sec-
tioned at 4 µm (3-4 sections per mouse), stained with hema-
toxylin, and examined under a light microscope (Olympus, 
BH-2) at ×400 magnification. Apoptotic cells were identi-
fied in 20 randomly chosen complete crypts by characteris-
tic morphological changes of cell shrinkage, condensed 
chromatin, and sharply delineated cell borders surrounded 
by an unstained halo.21,37 The percentage of apoptotic cells 
were calculated as the mean number of apoptotic cells/
crypt, divided by total number of cells in the crypt and mul-
tiplied by 100. The height of each crypt was determined 
along with the position of apoptotic cells.38
Determination of Epithelial Proliferation 
(Immunohistochemical Staining)
Ki-67 is a cell cycle–associated antigen and regarded as a 
useful epithelial cell proliferation marker.39 Distal colon seg-
ments were embedded in paraffin then sectioned at 4 µm. 
Sections were de-waxed in Histoclear and hydrogen perox-
ide (3%) was used for 15 minutes to quench the endogenous 
Esmaeelian et al 251
peroxidase activity. Antigen retrieval was achieved by cook-
ing the sections in a pressure cooker at 120°C for 1 hour in 
0.1 mol/L citrate buffer (pH 6.5). Sections were incubated 
with a primary monoclonal Ki-67 antibody (1:1000; Dako) at 
4°C overnight. For detection of the primary antibody, bioti-
nylated secondary rabbit-anti-mouse antibody (1:200; Dako) 
for 30 minutes and avidin/biotinylated peroxidase complex 
(Signet Laboratories USA-HRP kit) for 20 minutes were 
used. Slides were visualized by incubating with 3′-diamino-
benzamine (DAB) substrate (Signet Laboratories USA-HRP 
kit) for 3 minutes, followed by counterstaining for 1 minute 
in hematoxylin and examining under a light microscope 
(Olympus, BH-2) at ×400 magnification. The percentage of 
proliferating cells was calculated in the same way as the 
apoptosis index described above.
Statistical Analysis
Statistical analyses were performed using SPSS (Smart 
Viewer 15.0) and/or Prism GraphPad (version 5.2), and P 
values of ≤.05 were considered to be statistically signifi-
cant. A one-way ANOVA test was performed to compare 
between treatments and controls across the different con-
centrations. Tukey HSD post hoc test was applied to detect 
which groups significantly differ. Levene test was used to 
check homogeneity of variances, and in all cases P > .05.
Results
Chemical Analysis
LC/MS analysis of Dicathais orbita crude extract revealed 
at least 5 peaks attributed to brominated indole compounds 
(Figure 1A). The dominant peak at t
R
 6.37 minutes occur-
ring with major ions in ESI-MS at m/z 224, 226 is indicative 
of the molecular mass of 6-bromoisatin. The mass spectrum 
of the peak at t
R
 9.35 minutes with major ions in ESI-MS at 
m/z 302, 304 corresponds to tyrindolinone. The small peak 
at t
R
 10.44 minutes is attributed to tyrindoxyl sulfate, with 
major ions in ES-MS at m/z 336, 338. The peak at t
R
 11.00 
minutes is indicative of the molecular weight of tyrindole-
ninone with major ions at m/z 255, 257, and a peak at t
R
 
11.71 minutes with ions in ESI-MS at m/z 511, 513, 515 
corresponding to the molecular mass of tyriverdin with 
major fragment ions at m/z 417, 419, 421 formed by the 
elimination of dimethyl disulfide. LC/MS analysis of the 
purified compounds showed a single peak at t
R
 11.00 min-
utes corresponding to tyrindoleninone (Figure 1B) and a 
dominant peak at t
R
 6.37 minutes corresponding to 6-bro-
moisatin with several other minor peaks (Figure 1C).
In Vivo Model: General Observations
There were no signs of illness (ie, no diarrhea, constipation, 
dysphagia, hematemesis, or loss of appetite) in any of the 
Figure 1. Liquid chromatography/mass spectrometry analysis 
of (A) crude extract from hypobranchial gland of Dicathais 
orbita, (B) purified tyrindoleninone, and (C) semipurified 
6-bromoisatin.
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treatment groups or control animals throughout the study. 
All animals groups were oral gavaged daily with sunflower 
oil only or sunflower oil containing treatments. The body 
weights of all mice increased steadily over the trial duration 
(Table 1); no significant differences in mean total weight 
gain was revealed either between the saline control and 
AOM control, or the AOM control group and treatment 
groups by analysis of variance (Table 1). The livers of all 
mice were excised and weighed at the end of the experi-
ment. The results showed a significant increase in the per-
cent liver to body weight (~25%) for the controls injected 
with AOM compared to saline (P ≤ .01). No significant 
change in the liver weight was revealed after AOM injec-
tion between oil control and any treatment group (Table 1).
Histopathology Evaluation of the Liver
Using light microscopy, the predominant histopathological 
alteration in the liver was the presence of numerous cyto-
plasmic vacuoles consistent with microvesicular steatosis 
(fatty liver), with varying degrees of sinusoidal dilation and 
congestion (Figure 2). This effect was visible 6 hours after 
injection with AOM, but not in the saline control (Figure 
2C). There were no further changes with regard to microve-
sicular steatosis (fatty liver), sinusoidal dilatation, or red 
blood cell extravasation into the space of Disse that could 
be discerned in the mice oral gavaged with either compound 
or extract, as compared to AOM injected controls, which 
were oral gavaged with oil only.
Liver Enzyme Analysis
Toxicity was monitored by quantitative analysis of the liver 
enzymes AST, ALT, and ALP, enzymes that are known bio-
chemical markers of liver toxicity. ALP level was similar 
between the 2 control groups and all treatment groups. ALT 
and AST levels were higher in AOM-injected controls com-
pared to saline-injected controls (Figure 3), but these were 
not significantly different. No significant differences were 
found in the ALT and AST blood levels between the AOM-
injected controls and all treatment groups, except for one 
tyrindoleninone group (0.1 mg/g). In this group a combined 
effect of AOM and tyrindoleninone was observed on the 
AST levels, and mice treated with tyrindoleninone (0.1 
mg/g) showed a significant AST blood level increase in 
comparison with the AOM-injected oil control (P ≤ .05).
Hematological and Biochemical Blood Analysis
Hematology results from the mouse blood samples includ-
ing red blood count, hemoglobin, hematocrit (Hct), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration 
(MCHC), white cell count, neutrophil number, lympho-
cytes, and monocytes are summarized in Table 2. Following 
2 weeks of oil control gavage only, AOM injection led to a 
significant reduction of lymphocytes compared to saline 
injection (P ≤ .01). By contrast, the number of neutrophils 
increased significantly 6 hours after injection with AOM 
compared to saline (P ≤ .05). In the treatment groups, red 
cell count and hemoglobin concentration showed a signifi-
cant reduction in the mice treated daily with 0.1 mg/g tyrin-
doleninone in comparison with AOM oil only control (P ≤ 
.05), whereas monocytes were significantly elevated in 
mice treated daily with the lower dose of 0.05 mg/g tyrindo-
leninone. White cell count and the number of neutrophils 
were reduced significantly in the group treated with the 
lower concentration 0.05 mg/g 6-bromoisatin compared to 
the oil only control after injection with AOM (P ≤ .05). 
However, the number of neutrophils in the 6-bromoisatin 
Table 1. Body and Liver Weights of Animals During the Experimenta,b.
Weight (g)
 Body (Day 1) Body (Day 5) Body (Day 10) Body (Day 14)
Total Weight 
Gain Liver Liver/Body (%)
Saline control 24.6 ± 1.1 25.0 ± 0.9 25.2 ± 1.0 25.1 ± 1.1 0.5 ± 0.4 1.1 ± 0.2 4.2 ± 0.6**
AOM control 24.2 ± 1.4 24.5 ± 1.4 25.1 ± 1.6 25.0 ± 1.6 0.7 ± 0.5 1.3 ± 0.1 5.3 ± 0.5
TYR 0.025 mg/g 22.9 ± 1.0 23.0 ± 1.1 23.9 ± 1.4 24.5 ± 1.7 1.6 ± 1.2 1.1 ± 0.1 4.7 ± 0.7
TYR 0.05 mg/g 23.9 ± 1.0 24.1 ± 1.2 24.8 ± 1.3 24.6 ± 1.2 0.7 ± 0.5 1.3 ± 0.1 5.2 ± 0.4
TYR 0.1 mg/g 23.0 ± 1.6 23.3 ± 1.5 23.6 ± 1.5 23.7 ± 1.6 0.6 ± 2.0 1.2 ± 0.2 5.3 ± 0.9
6-BRO 0.05 mg/g 24.9 ± 0.9 25.1 ± 1.2 25.5 ± 1.2 25.5 ± 1.3 0.6 ± 0.9 1.2 ± 0.1 4.8 ± 0.4
6-BRO 0.1 mg/g 25.9 ± 1.1 25.8 ± 1.3 26.2 ± 1.4 26.4 ± 1.4 0.5 ± 0.5 1.4 ± 0.1 5.2 ± 0.2
CE 0.25 mg/g 24.7 ± 1.2 25.3 ± 1.3 25.7 ± 1.6 26.1 ± 1.6 1.4 ± 0.6 1.4 ± 0.1 5.3 ± 0.5
CE 0.5 mg/g 24.0 ± 2.0 24.5 ± 2.1 24.5 ± 2.4 25.1 ± 2.3 1.1 ± 0.4 1.3 ± 0.2 5.2 ± 0.5
Abbreviations: TYR, tyrindoleninone; 6-BRO, semipurified 6-bromoisatin; CE, crude extract; AOM, azoxymethane.
aN = 10 mice in all groups.
bComparison of mean (±SE) progressive body weight (g) in control and treatment mice on different experimental days. Liver weight (g) and percent of 
liver weight/body weight were calculated on the day of kill.
**P ≤ .01 between the AOM- and saline-injected oil controls.
Esmaeelian et al 253
treatment group (0.05 mg/g) was not significantly different 
to that observed in the saline injected control.
The concentration of blood biochemical parameters such 
as sodium, potassium, sodium/potassium ratio (Na/K), urea, 
creatinine, calcium, protein, albumin, and globulin were 
also measured (Table 3). There was a significant elevation 
(P ≤ .001) in the urea level of the oil control after AOM 
injection (11.81 ± 1.39 mmol/L) in comparison to saline 
injection (9.01 ± 1.62 mmol/L). Globulin protein level was 
decreased significantly, but not with a clear dose-dependent 
response, in the mice administered tyrindoleninone (Table 
3). Conversely, 6-bromoisatin (0.05 mg/g) increased the 
level of globulin in comparison to the oil control after AOM 
injection.
Apoptotic Index and Crypt Height
Apoptotic cells were rarely detected in the crypts of the dis-
tal colon following saline injection, whereas in response to 
AOM injection, a low background level of apoptosis was 
initiated (see Figure 4A and Supplementary Figure 1A and 
B, available online at http://ict.sagepub.com/supplemental). 
Apoptosis significantly increased in the distal colon of mice 
administered semipurified 6-bromoisatin, at both concen-
trations of 0.05 mg/g and 0.1 mg/g (P ≤ .001) compared to 
the oil control (by 2.5-fold) after AOM injection. A 
significant increase in the apoptotic index after AOM injec-
tion was also revealed between oil gavaged control mice 
and those administered 0.25 mg/g (P ≤ .05) and 0.5 mg/g (P 
≤ .001) of crude extract, with a clear dose effect (Figure 
4A). In contrast, there was no significant difference in 
apoptotic index after AOM injection between mice treated 
with tyrindoleninone and those gavaged oil only. Mean 
crypt height in distal colon was similar between the AOM 
injected and saline injected control (Figure 4B). However, 
after AOM injection, 2 treatment groups showed a signifi-
cant decrease in mean crypt height, 0.025 mg/g tyrindoleni-
none (P ≤ .05) and 0.5 mg/g crude extract (P ≤ .05), in 
comparison to the oil control (Figure 4B).
Proliferation Index
Mean proliferation index in the distal colon was not signifi-
cantly different between the AOM- and saline-injected oil 
controls (Figure 4C). However, after AOM injection, cell 
proliferation was reduced significantly in mice treated with 
semipurified 6-bromoisatin at concentrations of 0.05 mg/g 
and 0.1 mg/g compared to the oil only control (P ≤ .001; see 
Figure 4C and Supplementary Figure 1C and D, available 
online at http://ict.sagepub.com/supplemental). Similarly 
after AOM injection, tyrindoleninone administration at 0.05 
(P ≤ .01) and 0.1 mg/g (P ≤ .001) resulted in a significant 
reduction of proliferation compared to the oil only control 
(Figure 4C). Tyrindoleninone at the 0.025 mg/g lowest con-
centration had no significant effect on the proliferation 
index (Figure 4C). A significant reduction in proliferative 
cells was also observed in mice treated with the crude 
extract at both concentrations of 0.25 and 0.5 mg/g (P ≤ 
.001; Figure 4C) after AOM injection.
Discussion
This study demonstrates for the first time that the short-term 
AARGC rodent model for colon cancer prevention can be 
Figure 2. Microscopic images of sectioned liver tissue (original 
magnification ×200 except “C,” which is ×400) from mice 
in control and treatment groups stained by hematoxylin and 
eosin. (A) Saline control; (B) AOM control; (C) AOM control 
(×400); (D) tyrindoleninone 0.025 mg/g; (E) tyrindoleninone 
0.05 mg/g; (F) tyrindoleninone 0.1 mg/g; (G) semipurified 
6-bromoisatin 0.05 mg/g; (H) semipurified 6-bromoisatin 0.1 
mg/g; (I) crude extract 0.25 mg/g; (J) crude extract 0.5 mg/g. 
Microvesicular steatosis (shown by arrow) was the predominant 
histopathological finding with varying degrees of sinusoidal 
dilatation (shown by arrow head) and congestion in all AOM-
injected mice after 6 hours.
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used to simultaneously collect preclinical in vivo data on 
efficacy and safety by including AOM and saline injection 
controls. Although some histopathological effects specific 
to AOM were detected in the liver, the effects of the extracts 
and compounds on liver function could be discerned from 
the levels of liver enzymes in blood. Furthermore, despite 
the fact that the carcinogen AOM appears to induce inflam-
matory neutrophils, synergistic and immune-modulating 
effects of the bioactive compounds could be detected by 
hematological assessments. This combined model revealed 
that both the crude muricid extract and semipurified 6-bro-
moisatin significantly increased the apoptotic index after 
administration of a DNA-damaging agent, and also inhib-
ited cell proliferation in the distal colon of mice, without 
any sign of toxicity. LC/MS analysis confirmed 6-bromois-
atin as the major compound in both the crude extract and 
semipurified 6-bromoisatin fraction and the enhanced bio-
activity within the semipurified fraction indicates that 
6-bromoisatin is the main chemopreventative agent in the 
muricid extract. In contrast, purified tyrindoleninone did 
not increase the apoptotic index after AOM injection, but 
significantly reduced the cell proliferation index in the dis-
tal colon, in a dose-dependent manner. In addition, there 
was some evidence for toxicity in the liver and mild anemia 
in the mice corresponding to the administration of tyrindo-
leninone. This information on the potential side effects is 
very useful for development and quality control of an opti-
mized nutraceutical from Muricidae hypobranchial glands. 
Tyrindoleninone is easily oxidized into 6-bromoisatin,26 so 
controlled oxidation of the extract could help reduce the 
previously reported idiosyncratic hepatotoxicity30 and 
improve the overall safety and efficacy of these marine 
mollusc extracts.
Liver histopathology showed evidence of hepatocyte 
damage within 6 hours due to the AOM injection, which was 
consistent with microvesicular steatosis and varying degree 
of sinusoidal dilation and congestion. These qualitative 
changes were observed in the oil control following a single 
AOM injection and no further effect was discernible in the 
mice treated for 14 days with either compound or extract in 
addition to the single AOM injection. Microvesicular steato-
sis with varying degrees of hemorrhagic congestion and 
necrosis was previously shown in 15-week-old male 
C57BL/6 mice following the injection of 100 mg/kg AOM 
and sacrificing the animals after reaching the coma stage of 
encephalopathy.24 In our study, no sign of necrosis or hemor-
rhage in the liver were observed 6 hours after injection using 
one tenth of this dose (10 mg/kg). However, some other 
hepatocyte alterations observed in mice livers in our study 
were consistent with those observed by Bémeur et al.24 In 
another histological study by Matkowskyj et al,40 the mice 
showed microvesicular steatosis after 2 hours and sinusoidal 
dilatation after 4 hours of high-dose AOM administration 
(100 mg/kg), while centrilobular necrosis was only apparent 
20 hours after AOM injection. Macroscopically in our study, 
the most striking alteration in the liver was the significant 
increase in the percent liver to body weight in the oil con-
trols compared to saline, just 6 hours after AOM injection. 
Hepatic enlargement in the liver has been reported in mice 
receiving 100 mg/kg AOM,41 and our study confirms that 
this effect can occur even at the lower dose of 10 mg/kg. 
Consequently, it is not possible to extract information on the 
potential histopathological damage to the liver or changes in 
liver weights in treatments tested using the AARGC rodent 
model for colon cancer, due to the rapid overriding short-
term effects of AOM.
Figure 3. Levels of the liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase 
(ALP) in blood (U/L) from control and treatment groups including purified tyrindoleninone (TYR), semipurified 6-bromoisatin (6-
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Nevertheless, it is possible to obtain a preliminary 
assessment of hepatotoxicity in the AARGC model using 
biochemical indicators in the blood. No significant differ-
ences in the level of the liver enzymes ALP, ALT, and AST 
were found between AOM- and saline-injected oil control 
mice in our study. Conversely, in a study by Bélanger et al,42 
a significant increase in the blood level of ALT and AST 
was detected after the injection of a very high dose of AOM 
(100 mg/kg) in C57BL6 male mice, followed by the devel-
opment of acute liver injury, encephalopathy, coma, and 
death in the animals. In our study, only a slight but nonsig-
nificant increase in ALT and AST levels was detected 6 
hours following the injection of the lower dose of AOM (10 
mg/kg) in the oil control group. Similarly, another study by 
Matkowskyj et al40 showed no significant differences in the 
levels of ALT in the blood of C57BL/6J mice following the 
injection of 0.1 mg/g AOM (56 ± 5 U/L) after 4 hours, com-
pared with a saline control (64 ± 14 U/L). However the 
same authors showed 20 hours after AOM administration 
the levels of ALT increased significantly with the presence 
of centrilobular necrosis in hepatocytes (5196 ± 126 U/L).40 
This indicates a longer period of time is required to induce 
necrosis in hepatocytes after administration of AOM and 
also highlights the correlation between hepatic necrosis and 
increased level of liver enzymes, especially ALT, in the 
mice blood. This finding, along with the treatment results 
from our study, demonstrate that blood liver enzymes can 
provide an early indicator of potential hepatotoxicity and 
that it is possible to obtain preliminary information on the 
effects of chemopreventative agents on the liver using the 
short-term AOM colon cancer model.
The muricid extracts and 6-bromoisatin appear to have 
little to no liver toxicity at the chemopreventative doses that 
were tested. Following AOM injection, no significant differ-
ences in the level of the liver enzymes ALP, ALT, or AST 
were found between oil-only controls and mice treated with 
oil containing the muricid extract or purified 6-bromoisatin. 
However, the combination of a single AOM injection and 2 
weeks daily tyrindoleninone oral gavage (0.1 mg/mL) 
caused a significant increase in AST, indicating the adminis-
tration of tyrindoleninone along with a DNA-damaging 
agent can lead to liver toxicity. AOM is metabolized by 
endogenous enzymes in the liver, primarily cytochrome 
P450 2E1 (CYP2E1) via hydroxylation of the methyl group 
to the genotoxic carcinogen methylazoxymethanol.43,44 The 
tyrindoleninone metabolism pathway has not yet been eluci-
dated. However, of the enzymes needed for endogenous 
indole metabolism in the intestinal mucosa, CYP2C1945 
plays a minor role in indole oxidation46 and glutathione-S-
transferase (GST)47 can mediate debromination in phase 2, 
after oxidation by CYP2E1.48 Therefore, tyrindoleninone 
could indirectly affect CYP2E1-associated AOM metabo-
lism and increase the immediate toxic side effects of AOM 
in the liver. However, this study also supports the suggestion 
Figure 4. Apoptosis, crypt height and proliferation in the 
epithelial cells of crypts in the distal colon after 14-day oral 
gavage of different concentrations of tyrindoleninone (TYR), 
semipurified 6-bromoisatin (6-BRO), and crude extract (CE). 
The purified compounds were tested at lower concentrations 
than the crude extract. All treatments and the AOM control 
were injected with 10 mg/kg AOM, a genotoxic carcinogen, 6 
hours prior to kill. (A) Apoptotic index, (B) crypt height, (C) 
proliferating epithelial cells were detected via immunostaining 
with the Ki-67 primary monoclonal antibody. Data are means ± 
SE for 10 mice per group (10 full crypts/animal). P ≤ 0.05 (*), P 
≤ .01 (**), and P ≤ .001 (***) between each treatment group and 
the AOM-injected oil control.
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that in vivo metabolism of indoles such as tyrindoleninone 
produce by-products, such as indoxyl sulfate,30 that could 
directly affect the liver. Methanthiol generation during 
hepatic metabolism of tyrindoleninone may also contribute 
to steatohepatitis.30 These metabolic by-products are not 
expected to form from 6-bromoisatin, which is consistent 
with the lack of significant effects on liver enzymes in mice 
treated with this compound. Although the crude extract con-
taining tyrindoleninone showed no significant effect on liver 
enzymes, our previous study showed significant dose-
dependent histopathological effects on the liver.30 This study 
identifies tyrindoleninone as the most likely compound 
responsible for the idiosyncratic liver damage in muricid 
extract, thus suggesting that semipurification is required for 
nutraceutical development.
The other notable change in biochemical factors was the 
decreased level of globulin protein in the mice administered 
tyrindoleninone, although this alteration was not dose-
dependent. Globulin and albumin proteins are 2 main serum 
proteins in the blood that are produced by the liver.49 
Therefore, decreased production of globulin could provide 
further evidence of the liver damage associated with the 
administration of tyrindoleninone. The mice treated with 
the highest concentration of tyrindoleninone (0.1 mg/g) 
also had a significantly lower red cell counts and hemoglo-
bin levels (12.4 ± 0.8 g/dL) compared to the oil-only con-
trols following AOM injection, thus indicating mild anemia 
in these mice. According to the chart for anemia severity in 
male mice established by the World Health Organization, 
the concentration ranges for mild anemia is 10.7 to 12.4 g/
dL.50,51 Interestingly when AOM was injected after 2 weeks 
of daily oral gavage with the medium dose of tyrindoleni-
none (0.05 mg/mL), there was also an increase in monocyte 
numbers compared to the AOM-only control, suggesting 
some potentially complex effects on the immune system. 
All this information from the blood parameters provides 
further evidence for toxic side effects associated with oral 
administration of tyrindoleninone that was apparent over 
and above any effects of the AOM.
By comparison, following injection with AOM, the mice 
administered the oil control showed signs of lymphopenia 
(low lymphocytes) and neutrophilia (high neutrophils) rela-
tive to the saline-injected oil control. This result suggests 
that AOM has direct effects on the immune system within 6 
hours of injection. Neutrophils have a protective role in 
response to infection in the host52 and can increase as part of 
the general stress response. For example, stress generated 
by poisons (eg, the heavy metal arsenic) can increase the 
blood level of neutrophils in mice.53 In a study by Haratym-
Maj,54 poisoning of the mice with the low dose of deltame-
thrin significantly elevated neutrophil levels in blood 
compared to the control group. Therefore, occurrence of 
neutrophilia in the AOM-injected oil control is likely to be 
related to stress from injecting the DNA damaging AOM in 
mice.
Interestingly, when semipurified 6-bromoisatin (0.05 
mg/g) was administered for 2 weeks prior to the AOM 
injection, this resulted in neutrophil numbers in the normal 
range (similar to saline-injected oil controls). This indicates 
that purified 6-bromoisatin may also have an anti-inflam-
matory effect that counteracts the neutrophilia associated 
with AOM injection. This is consistent with the known anti-
inflammatory activity of isatin, which has been shown to 
inhibit inducible nitric oxide synthase, cyclooxygenase-2, 
and tumor necrosis factor, resulting in a reduction of prosta-
glandin E2 in mouse macrophages.55 In contrast, 0.05 mg/g 
purified 6-bromoisatin did not counteract the decrease of 
lymphocytes that occurs after AOM injection and actually 
lead to significantly less white blood cells compared to the 
AOM control. However, this was a dose-dependent effect, 
and in our previous studies using synthetic 6-bromoistain, 
there was a significant increase on white blood cells at the 
same dose.56 These variable effects on white blood cells 
between purified and synthetic 6-bromoisatin suggest that 
further studies should be conducted on the influence of the 
muricid bioactive brominated indoles on the vertebrate 
immune system.
The most striking alteration among the biochemical fac-
tors was the significant increase of the blood urea levels in 
oil-only controls, when AOM was injected compared to 
saline. Urea, which is the end product of protein metabo-
lism, is produced from ammonia in urea cycle57 and excreted 
through the kidney in urine. Consequently, the rate of renal 
urea excretion directly affects the maintenance of nitrogen 
balance in blood.58 In a study by Bémeur et al,24 AOM-
injected mice showed a significant 5.1-fold increase in 
ammonia concentration of the serum compared to the 
saline-injected mice. The increased concentration of ammo-
nia caused by AOM injection in Bémeur et al24 is consistent 
with the increased concentration of blood urea induced by 
AOM injection in our study. Urea serum concentration is 
used as a marker of renal function and is increased by renal 
injury.59 Thus, our study indicates AOM results in rapid 
injury (within 6 hours) to the kidney, as well as to the liver. 
However, mice treated with the crude muricid extract and 
compounds did not show any increase in urea compared to 
the oil controls, indicating no further toxicity of these com-
pounds in the kidney after 2 weeks of administration. In our 
previous study on synthetic 6-bromoisatin, a diuretic effect 
was found with increased sodium/potassium ratios in all 3 
doses that were tested (0.1-0.025 mg/g).56 However, no sig-
nificant effects on the ion balance was observed using the 
naturally derived semipurified 6-bromoistain in this study. 
This suggests that differences in the minor impurities of the 
naturally derived and synthetic compound could alter some 
in vivo effects.
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The inhibition of CRC has been previously linked with 
AARGC enhancement.19,60,61 The work presented here 
demonstrates that the crude extract (0.25 and 0.5 mg/g) has 
a dose-dependent effect, inducing apoptosis, in the distal 
colon of mice and at the same time reducing cell prolifera-
tion in the colon. Previous work on the muricid extract in 
our laboratory reported a significant increase in the apop-
totic index in the distal colon at the high 1.0 mg/g dose, but 
no effect on cell proliferation, whereas at the lower dose of 
0.125 mg/g, there was no significant effect on apoptosis, but 
an unexpected increase in cell proliferation.29 Thus, this lat-
est in vivo study has allowed us to identify the minimum 
crude dose required for significant protective effects (0.25 
mg/g). It is important to optimize the lowest effective dose 
for potential nutraceutical development of natural extracts. 
At the same time this study has confirmed that the chemo-
preventative effects are primarily associated with a purified 
fraction containing mostly 6-bromoisatin, which is active at 
even lower doses than the crude extract.
The in vivo results observed with the semipurified 6-bro-
moisatin are consistent with our previous in vitro work, 
which showed that naturally derived 6-bromoisatin could 
induce apoptosis via activating caspase-3 and -7 enzymes 
and reduce cell proliferation in both human colon adenocar-
cinoma (HT29) and human epithelial colorectal adenocarci-
noma (Caco-2).28 By comparison, synthetic 6-bromoisatin 
did not effectively induce apoptosis in CRC cells in vitro, 
but when tested in vivo, it did show the ability to signifi-
cantly increase the apoptosis index and reduce cell prolif-
eration in the distal colon of mice at the concentration of 
0.05 mg/g,56 in a similar fashion to the muricid-derived 
6-bromoisatin reported here. Some structurally similar 
isatin and indole compounds have been also shown to 
induce apoptosis in a range of cancer cell lines.62-64 For 
example, 5,6,7-tribromoisatin at a concentration of 8 µM 
induced apoptosis through activation of caspase-3/-7 in the 
Jurkat cell line.62 Together these data highlight the potential 
for developing simple naturally derived brominated isatin 
derivatives for the prevention or treatment of cancer.
Tyrindoleninone, on the other hand, did not significantly 
increase the apoptosis index in the distal colon of mice and 
in vivo it also elicited some toxic effects. In vitro studies in 
our laboratory revealed that 195 µM (0.05 mg/mL) tyrindo-
leninone significantly induced apoptosis by activating cas-
pase-3 and -7 activity in HT29 cell line, while this compound 
caused necrosis but not apoptosis in Caco-2 cells.28 In con-
trast, Edwards et al demonstrated that 20 µM tyrindoleni-
none significantly induced apoptosis in the KGN cell line.27 
Combined these results indicate that the apoptotic effects of 
tyrindoleninone in vitro are cancer cell line or tissue type 
specific, and in combination with the lack of in vivo activity 
and potential for toxic effects on the liver and red blood cells 
observed in this study, this compound is of lower priority for 
future development as a colon cancer preventative agent. 
Tyrindoleninone is a relatively unstable compound that is 
easily oxidized to form 6-bromoisatin,26 and it appears to be 
degraded on exposure to simulated gastric fluid.29 By com-
parison, 6-bromoisatin is a relatively stable compound that 
increases in the extract after exposure to digestive fluid,29 
and it can be easily quantified using a validated method for 
quality control.65 Consequently, by confirming the benefi-
cial effects of 6-bromoisatin, as opposed to tyrindoleninone, 
the present study provides an important advance for the 
strategic development of Muricidae molluscs as functional 
foods and nutraceuticals. Recent studies have confirmed 
that 6-bromoisatin and tyrindoleninone can be selectively 
concentrated by supercritical fluid extraction,66 thus provid-
ing an efficient alternative to traditional solvent extraction 
that is safe for nutraceutical production. Following on from 
this study, future work can focus on optimizing the purifica-
tion and formulation of 6-bromoistain from Dicathais orbita 
for nutraceutical development and testing in longer term ani-
mal trials.
Conclusion
In conclusion, our study has confirmed the ability to simul-
taneously collect preliminary toxicity information in a 
short-term AOM model for colon cancer prevention using 
appropriate saline and AOM controls. More specifically, we 
have shown that it is possible to monitor for general signs of 
ill health in the 2 weeks prior to AOM injection, in addition 
to collecting useful end-point data on blood cell counts, 
blood biochemistry, and plasma liver enzymes, despite the 
fact that AOM causes histopathological damage to the liver. 
Using this approach, we have determined that both semipu-
rified 6-bromoisatin and a crude extract from Muricidae 
molluscs enhanced the apoptotic response to a genotoxic 
carcinogen in the crypt of the distal colon, without any 
apparent toxic side-effects. 6-Bromoisatin was found to be 
the main chemopreventative agent in the extract, signifi-
cantly enhancing apoptosis and reducing cell proliferation 
in the colonic crypts at the lowest dose of 0.05 mg/g. Our 
results also showed some potentially toxic effects of puri-
fied tyrinoleninone on red blood cells and on liver enzymes 
(when combined with AOM), but without any efficacy in 
increasing AARGC. By comparison, 6-bromisatin, in addi-
tion to its efficacy, appears to have some immune-modula-
tory effects and is relatively more stable, and thus is a more 
useful target for optimizing as a nutraceutical from muricid 
extracts for further development as a CRC preventative. 
Longer term animal models are required to determine the 
effect of crude extract and 6-bromoisatin on pre-neoplastic 
lesions or ACF formation. Further studies to assess any pos-
sible side effects corresponding to the long-term adminis-
tration of these compounds would also be of interest.
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